Discontinued — last reported Q4 '16
Roivant Sciences Short-Term Investments decreased by 5.9% to $2.87B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 32.3%, from $2.17B to $2.87B. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests the company is effectively deploying excess cash to earn returns; a decrease may indicate cash usage for operations or acquisitions.
These are marketable securities and other financial instruments that the company intends to hold for more than three mon...
Common for companies with significant cash reserves and active treasury management.
short_term_investments| Q1 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $3.43B | $3.16B | $2.17B | $3.26B | $3.15B | $3.05B | $2.87B |
| QoQ Change | — | — | -7.9% | -31.2% | +50.3% | -3.5% | -3.1% | -5.9% |
| YoY Change | — | — | — | — | — | -8.1% | -3.3% | +32.3% |